Whether you want to refer a patient, join as an investigator site, access evidence briefings, or explore a research partnership — this page is your starting point.
KCLEAGENICS MEDICAL exists at the intersection of clinical practice and research. We recognise that the most important link in translating trial evidence into patient benefit is the clinician — the oncologist, haematologist, or GP who has the relationship with the patient and the clinical judgement to act on new evidence.
Our model is built around supporting you: providing timely, evidence-based intelligence, making patient referral straightforward, and offering site partnership arrangements that minimise administrative burden while maintaining the research quality that makes our findings publishable and practice-changing.
We are experienced in working within NHS systems — navigating ethics, R&D approval, information governance, and honorary contracts — so that participation in our trials is as operationally light as possible for you and your team.
We aim to respond to all clinician enquiries within 1 working day.
If you have a patient who may be eligible for one of our active studies, here is how to refer quickly and what to include.
Consider referring if your patient: has R/R CLL or SLL, is on or eligible for ibrutinib, is treated at an NHS haematology centre, has no contraindication to statin therapy, and has adequate performance status (ECOG 0–2).
Consider referring if your patient: has a solid tumour with ≥1 prior line of therapy, has adequate tumour tissue for molecular profiling, has ECOG PS 0–2, and is treated at or can be referred to a participating site.
We work with NHS Trusts and academic centres as participating sites for our trials, offering full site management support so you can focus on clinical care and research delivery.
We translate our research findings — and the broader oncology evidence base — into clear, clinician-focused briefings designed for busy clinical practice.
A curated monthly digest of trial updates, methodology commentary, and practice-relevant evidence reviews — written for NHS consultants, registrars, and specialist nurses.
Structured summaries of landmark trials and meta-analyses relevant to our research areas — haematological malignancies, precision oncology, immunotherapy, and cancer risk.
Regular updates on recruitment progress, interim safety data, and protocol amendments for all KCLEAGENICS MEDICAL active studies — shared with referring clinicians and site investigators.
Join our trial as a named co-investigator — contributing to protocol development, patient recruitment at your site, and, where appropriate, co-authorship of publications.
Refer eligible patients to our studies without taking on trial management responsibilities. We handle all research administration and keep you informed of your patient's progress.
If you hold research funding or are developing a grant application, we can provide the regulatory, operational, and statistical infrastructure to turn your proposal into a running trial.
